header.html

An official website of the European Union How do you know?      
European Commission logo

handle.jsp

cover
The paper describes in vitro cytotoxicity experiments with 213-Bi- and 225-Ac-immunoconjugates on the human epidermoid tumour cell line A431 using a blood group A-reactive murine IgG (2D11) as the specific antibody and MOPC 21 as the control antibody. With both radionuclides, specific cell-killing was achieved. The observed cytotoxicity of 213-Bi (T 1/2 = 47 min) indicates that this radionuclide is a useful alternative for the alpha-emitter 212-Bi in the treatment of blood-borne malignancies. 225-Ac-immuno-conjugates may be applicable for the treatment of solid tumours, since the daughter radionuclides of 225-Ca contribute to the cytotoxic efficacy by a field effect (i.e. toxicity in an area distal from antibody-binding site). The lack of an adequate chelator for 225-Ac is a major drawback.
1996-08-12
JRC13471
https://publications.jrc.ec.europa.eu/repository/handle/JRC13471,   
NameCountryCityType
Datasets
IDTitlePublic URL
Dataset collections
IDAcronymTitlePublic URL
Scripts / source codes
DescriptionPublic URL
Additional supporting files
File nameDescriptionFile type 

footer.html